For research use only. Not for therapeutic Use.
Dolasetron (Cat No.: I000577) is a selective serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by chemotherapy, radiation, and surgery. It works by blocking serotonin receptors in the central nervous system and gastrointestinal tract, reducing emetic signals to the brain. Dolasetron is available in oral and intravenous forms, with its active metabolite, hydrodolasetron, providing prolonged antiemetic effects. While generally well-tolerated, side effects may include headache, dizziness, and QT interval prolongation, necessitating caution in patients with cardiac conditions.
| CAS Number | 115956-12-2 |
| Synonyms | octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, 1H-indole-3-carboxylic acid, stereoisomer |
| Molecular Formula | C19H20N2O3 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | 10 mM in DMSO |
| Storage | -20°C |
| IUPAC Name | [(3S,7R)-10-oxo-8-azatricyclo[5.3.1.03,8]undecan-5-yl] 1H-indole-3-carboxylate |
| InChI | 1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11?,12-,13+,14? |
| InChIKey | UKTAZPQNNNJVKR-MMUVGSQPSA-N |
| SMILES | C1[C@@H]2CC(C[C@H]3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54 |
| Reference | </br>1:Erratum: Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy [Erratum]. [No authors listed]Cancer Manag Res. 2016 Jun 28;8:83. doi: 10.2147/CMAR.S115369. eCollection 2016. PMID: 27390532 Free PMC Article</br>2:Long-term Use of Ondansetron, Dolasetron and Granisetron for the Prevention of Nausea and Vomiting: A Review of the Clinical Effectiveness and Safety [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Apr 23. PMID: 25610941 Free Books & Documents</br>3:Perioperative doses of ondansetron or dolasetron do not lengthen the QT interval. Obal D, Yang D, Sessler DI.Mayo Clin Proc. 2014 Jan;89(1):69-80. doi: 10.1016/j.mayocp.2013.10.008. PMID: 24388024 </br>4:Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D.Support Care Cancer. 2014 Feb;22(2):469-77. doi: 10.1007/s00520-013-1999-9. Epub 2013 Oct 19. PMID: 24141698 Free PMC Article</br>5:Optimization of sample pretreatment methods for simultaneous determination of dolasetron and hydrodolasetron in human plasma by HPLC-ESI-MS. Hu Y, Chen S, Chen J, Liu G, Chen B, Yao S.J Chromatogr Sci. 2012 Oct;50(9):785-91. doi: 10.1093/chromsci/bms065. Epub 2012 May 29. PMID: 22645289 </br>6:Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Roberts SM, Bezinover DS, Janicki PK.Cancer Manag Res. 2012;4:67-73. doi: 10.2147/CMAR.S15545. Epub 2012 Feb 24. Erratum in: Cancer Manag Res. 2016;8:83. PMID: 22427733 Free PMC Article</br>7:Retraction note to: Dolasetron, but not metoclopramide prevents nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Miller DR.Can J Anaesth. 2011 Sep;58(9):885, 885-6. doi: 10.1007/s12630-011-9531-5. English, French. No abstract available. PMID: 21792705 </br>8:Placebo-controlled comparison of dolasetron and metoclopramide in preventing postoperative nausea and vomiting in patients undergoing hysterectomy: Retraction. [No authors listed]Eur J Anaesthesiol. 2011 Jun;28(6):469. doi: 10.1097/EJA.0b013e328347b41c. No abstract available. PMID: 21540659 </br>9:Dolasetron for preventing postanesthetic shivering: Retraction. [No authors listed]Anesth Analg. 2011 May;112(5):1211. doi: 10.1213/ANE.0b013e31821a9648. Epub 2011 Mar 30. No abstract available. PMID: 21451086 </br>10:A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Vergne-Salle P, Dufauret-Lombard C, Bonnet C, Simon A, Trèves R, Bonnabau H, Bertin P.Eur J Pain. 2011 May;15(5):509-14. doi: 10.1016/j.ejpain.2010.09.013. Epub 2010 Oct 30. PMID: 21036635 |
